Rifaat Safadi

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡

Ting‐Tsung Chang, Yun‐Fan Liaw, Shun-Sheng Wu et al. · Hepatology · 2010 · 977 citations · Full text

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

Rifaat Safadi, Fred M. Konikoff, Mahmud Mahamid et al. · Clinical Gastroenterology and Hepatology · 2014 · 270 citations · Full text

Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC

Alaa Melhem, Nidal Muhanna, Amal Bishara et al. · Journal of Hepatology · 2006 · 265 citations

Inflammation, Hepatology, Medicine +15